Lemonade is light years ahead of competitors in agentic insurance as policies shift from set-and-forget to hundreds of micro-interactions each year. It is the first company to truly enter this model while incumbents still work on AI premium-pricing models. Pet insurance involves frequent small claims, and car telematics keeps updating driving-based prices and safety assessments. x.com 

Lemonade looks expensive once valued as what it is, an insurance company. Replying to @javierluraschi's post on the stock, any price above 1x revenue is expensive for an insurer. x.com 

Lemonade is reducing transparency on a key indicator of whether it can scale efficiently. Earnings reports once showed in-force premium versus opex, then switched to premium versus employee count, presumably as opex rose, and now show premium alone. Investors are tiring of waiting for EBITDA profitability, and the missing comparative metrics give less insight into how Lemonade gets there. The stock had run ahead into earnings, so a reset was due without a blowout. x.com  x.com 

Lemonade's approach to building an AI-agent insurance platform could become the global standard. Building a complete way for agents to buy, renew or file claims through Lemonade OS is brilliant; the company is building for the agentic era. x.com 

Lemonade's business thesis has not broken; the stock is falling on normal high-beta behavior, not fundamentals. With beta over two, high short interest and no profits yet, it moves sharply with risk appetite. Co-founder Daniel Schreiber's share sales are normal for a founder with concentrated wealth, though their framing was tone deaf, and stock pay is needed to hire engineers against Google and Meta. Long-term holders should watch in-force premium growth, loss ratio and operating leverage. … Show more

Lemonade's share-price drop after a great second quarter is a wild overreaction. Per its Q2 2026 results, in-force premium rose 32.4% to $1.43 billion and revenue grew 79% to $294 million, the 11th straight quarter of accelerating growth, with over 3.3 million customers. x.com  x.com 

Lemonade and Tempus AI are where AI returns become visible, as capital moves from infrastructure up to the application layer. Big Tech's hundreds of billions in AI capex still show little attributable revenue and no clear moat beyond scale, and infrastructure depreciates. Lemonade's marketing buys customer relationships that can last decades and improve underwriting; Tempus's clinical dataset grows harder to replicate with each patient, backing pharma revenue with 126% NRR. x.com 

Lemonade is one of the best buys in the market because its AI model lets it scale customers, products and revenue without scaling headcount. In-force premium grew 32% YoY, its tenth straight quarter of acceleration, and doubled over three years as headcount fell; revenue tripled while gross profit grew 10x. Up to 50% discounts for miles driven on Tesla FSD show an edge traditional insurers can't copy. It should be EBITDA profitable in Q4 2026, yet the stock fell 50% in four months. x.com  x.com 

SiTime, Tempus AI and Lemonade look like AI beneficiaries that need not rely on rising frontier-model spending, unlike a crowded trade vulnerable to concentrated capital and circular financing. SiTime can expand into robotics even if data-center growth slows; clinical decisions still need Tempus; Lemonade's models may improve loss ratios and retention while lower compute costs could help it. x.com 

Lemonade's cash burn makes its promotion by paid influencers on X suspect. Its shares are down 38% year to date, alongside other heavily promoted stocks. x.com